Format
Sort by
Items per page

Send to

Choose Destination

Best matches for hourigan_cs:

Search results

Items: 1 to 20 of 74

1.

Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation.

Ghannam JY, Xu X, Maric I, Dillon L, Li Y, Hsieh M, Hourigan CS, Fitzhugh CD.

Blood. 2020 Feb 14. pii: blood.2019004001. doi: 10.1182/blood.2019004001. [Epub ahead of print] No abstract available.

PMID:
32062672
2.

Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia.

Çelik H, Lindblad KE, Popescu B, Gui G, Goswami M, Valdez J, DeStefano C, Lai C, Thompson J, Ghannam JY, Fantoni G, Biancotto A, Candia J, Cheung F, Sukumar G, Dalgard CL, Smith RH, Larochelle A, Dillon LW, Hourigan CS.

Blood Adv. 2020 Jan 28;4(2):367-379. doi: 10.1182/bloodadvances.2019001124.

3.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.

J Clin Oncol. 2019 Dec 20:JCO1903011. doi: 10.1200/JCO.19.03011. [Epub ahead of print]

PMID:
31860405
4.

MRD evaluation of AML in clinical practice: are we there yet?

Freeman SD, Hourigan CS.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):557-569. doi: 10.1182/hematology.2019000060.

PMID:
31808906
5.

Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.

Ghannam J, Dillon LW, Hourigan CS.

Br J Haematol. 2020 Jan;188(1):77-85. doi: 10.1111/bjh.16362. Epub 2019 Dec 5. Review.

PMID:
31804716
6.

Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Othus M, Gale RP, Hourigan CS, Walter RB.

Bone Marrow Transplant. 2019 Oct 30. doi: 10.1038/s41409-019-0729-4. [Epub ahead of print]

PMID:
31666655
7.

Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation.

McReynolds LJ, Zhang Y, Yang Y, Tang J, Mulé M, Hsu AP, Townsley DM, West RR, Zhu J, Hickstein DD, Holland SM, Calvo KR, Hourigan CS.

Leuk Res Rep. 2019 Jun 10;12:100176. doi: 10.1016/j.lrr.2019.100176. eCollection 2019.

8.

Heterogeneity in refractory acute myeloid leukemia.

Horibata S, Gui G, Lack J, DeStefano CB, Gottesman MM, Hourigan CS.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10494-10503. doi: 10.1073/pnas.1902375116. Epub 2019 May 7.

9.

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

Lai C, Ranpura V, Wu C, Olnes MJ, Parikh AR, Shenoy A, Thompson J, Weinstein B, Scheinberg P, Barrett AJ, Desmond R, Young NS, Hourigan CS.

Blood Adv. 2019 Apr 9;3(7):980-983. doi: 10.1182/bloodadvances.2018030411. No abstract available. Erratum in: Blood Adv. 2019 Jun 11;3(11):1657.

10.

The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.

Palangat M, Anastasakis DG, Fei DL, Lindblad KE, Bradley R, Hourigan CS, Hafner M, Larson DR.

Genes Dev. 2019 May 1;33(9-10):482-497. doi: 10.1101/gad.319590.118. Epub 2019 Mar 6.

11.

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Wong HY, Sung AD, Lindblad KE, Sheela S, Roloff GW, Rizzieri D, Goswami M, Mulé MP, Ramos NR, Tang J, Thompson J, DeStefano CB, Romero K, Dillon LW, Kim DY, Lai C, Hourigan CS.

Front Oncol. 2019 Jan 15;8:669. doi: 10.3389/fonc.2018.00669. eCollection 2018.

12.

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

McReynolds LJ, Yang Y, Yuen Wong H, Tang J, Zhang Y, Mulé MP, Daub J, Palmer C, Foruraghi L, Liu Q, Zhu J, Wang W, West RR, Yohe ME, Hsu AP, Hickstein DD, Townsley DM, Holland SM, Calvo KR, Hourigan CS.

Leuk Res. 2019 Jan;76:70-75. doi: 10.1016/j.leukres.2018.11.013. Epub 2018 Dec 4.

13.

Refining AML outcome prediction.

Hourigan CS, Gale RP, Walter RB.

Leukemia. 2019 Feb;33(2):283-284. doi: 10.1038/s41375-018-0317-4. Epub 2018 Dec 14. No abstract available.

PMID:
30552400
14.

Pathogenic TERT promoter variants in telomere diseases.

Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW, Clé DV, Santana BA, Pirooznia M, Ibanez MDPF, Townsley DM, Kajigaya S, Hourigan CS, Cooper JN, Calado RT, Young NS.

Genet Med. 2019 Jul;21(7):1594-1602. doi: 10.1038/s41436-018-0385-x. Epub 2018 Dec 7.

15.

Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry.

Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, Dillon LW, McCoy JP, Hourigan CS.

JCI Insight. 2018 Dec 6;3(23). pii: 124928. doi: 10.1172/jci.insight.124928.

16.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

17.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

18.

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.

Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK.

Neurosurgery. 2019 Apr 1;84(4):945-953. doi: 10.1093/neuros/nyy392.

PMID:
30189044
19.

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.

Dillon LW, Hayati S, Roloff GW, Tunc I, Pirooznia M, Mitrofanova A, Hourigan CS.

Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.

20.

Leukaemia risk associated with low-dose radiation.

Hourigan CS, Savani BN.

Lancet Haematol. 2018 Aug;5(8):e324-e325. doi: 10.1016/S2352-3026(18)30106-6. Epub 2018 Jul 17. No abstract available.

Supplemental Content

Loading ...
Support Center